Boston, MA 08/19/2014 (wallstreetpr) – Biopharmaceutical company Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) had received a favorable comment from Deutsche Bank analyst on the improvement of its execution of clinical trial, which was one of the key concerns until recently.
Positive Comment
The investment advisor’s analyst, Alethia Young, viewed the recent appointment of a fresh CMO as increasing the management expertise. The analyst had also allayed concerns on clinical and management execution and said that they were showing signs of improvement. The brokerage base case assumed a 40% chance of success rate.
Terming that Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) remained a takeover target, Young said that every 10% of probability of success for the nuke or POS was valued around $5 – $6 a share. The analyst assumed the company’s peak sales of $3 billion, i.e. 10% peak share, in 2018 with a 5% lower price point compared to Gilead Sciences, Inc. (NASDAQ:GILD).
Deutsche Bank viewed Nuke as essential for competitive long-term course of therapy in HCV. Presently, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co., Inc. (NYSE:MRK) were either in the market or in the development of nukes.
Rating Of Stock
As a result of favorable factors, the brokerage had upgraded its rating on Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares to Buy from Hold rating. The analyst was not content with the changes in rating alone and preferred to boost the price objective too.
Deutsche Bank analyst Young had lifted his price target to $17 from $6 on the shares of Achillion Pharmaceuticals. The increase in price objective was significant by $11 or 183.3% from his previous price tag. The revised price target presents a potential upside reward of 78.2% from the Monday’s closing price of $9.54.
Stock Price
The stock has a 52-week low of $2.26 and a high of $10.10 reached on August 18. On Monday, the company’s shares witnessed a trading volume of 16.9 million shares compared to the three-month-average volume of 7.17 million shares. On August 15 too, 21.9 million shares changed hands compared to 4.7 million, 2.9 million, 2 million, and 4.6 million volume in the preceding four days of trading. The recent uptick in volume only suggests a fresh interest among interests to shop the stock ahead of any fresh developments, including a takeover proposal.
